Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19.
Identifieur interne : 000F04 ( Main/Exploration ); précédent : 000F03; suivant : 000F05Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19.
Auteurs : Norma Francenia Santos-Sánchez [Mexique] ; Raúl Salas-CoronadoSource :
- Medwave [ 0717-6384 ] ; 2020.
Descripteurs français
- KwdFr :
- Betacoronavirus (classification), Betacoronavirus (isolement et purification), Facteurs de risque (MeSH), Facteurs âges (MeSH), Humains (MeSH), Infections à coronavirus (diagnostic), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Pandémies (MeSH), Pneumopathie virale (diagnostic), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Techniques de laboratoire clinique (MeSH).
- MESH :
- diagnostic : Infections à coronavirus, Pneumopathie virale.
- isolement et purification : Betacoronavirus.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- classification : Betacoronavirus, Facteurs de risque, Facteurs âges, Humains, Pandémies, Techniques de laboratoire clinique.
English descriptors
- KwdEn :
- Age Factors (MeSH), Betacoronavirus (classification), Betacoronavirus (isolation & purification), COVID-19 (MeSH), COVID-19 Testing (MeSH), COVID-19 Vaccines (MeSH), Clinical Laboratory Techniques (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Risk Factors (MeSH), SARS-CoV-2 (MeSH).
- MESH :
- classification : Betacoronavirus.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- isolation & purification : Betacoronavirus.
- Age Factors, COVID-19, COVID-19 Testing, COVID-19 Vaccines, Clinical Laboratory Techniques, Humans, Pandemics, Risk Factors, SARS-CoV-2.
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes COVID-19 (Coronavirus disease 2019). This disease was detected in the city of Wuhan in China in December 2019. People infected with COVID-19 shows varying manifestations, depending on their health and age. The most common symptoms are fever, cough, myalgia, fatigue, odynophagia, and dyspnea. Infected adults older 60 years of age are the group of patients most susceptible to severe COVID-19 states and present comor-bidity in the presence of chronic diseases. On the other hand, it is also essential to have tests to detect SARS-COV-2 in people and follow the evolution of COVID-19 quickly, reliably, and cheap. To achieve this, there are real-time reverse transcription pol-ymerase chain reaction (RT-PCR) tests, isothermal nucleic acid amplification, and enzyme immunostimulation. Currently, there are no drug treatments to prevent infection and to combat the virus's effects. However, different research groups that are conduct-ing in vitro, in vivo, and in silico tests to find drugs able to provide an immune response and to control infection in humans with SARS-CoV-2. Chloroquine, hydroxychloroquine, remdesivir, interferon-2b, and oseltamivir are some pharmacological options evaluated in clinical trials for prophylaxis of COVID-19. The purpose of this review is to establish a reference framework for taxonomic classification of SARS-CoV-2 and the relationship they have with other CoVs, as well as their structure and propaga-tion pathways in humans. The characteristics and symptoms presented by patients with COVID-19, the detection methods, and possible treatments are also presented.
DOI: 10.5867/medwave.2020.08.8037
PubMed: 33017386
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19.</title><author><name sortKey="Santos Sanchez, Norma Francenia" sort="Santos Sanchez, Norma Francenia" uniqKey="Santos Sanchez N" first="Norma Francenia" last="Santos-Sánchez">Norma Francenia Santos-Sánchez</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca, México. ORCID: 0000-0001-5094-0488.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Mexique</country><wicri:regionArea>Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca</wicri:regionArea><wicri:noRegion>Oaxaca</wicri:noRegion></affiliation></author><author><name sortKey="Salas Coronado, Raul" sort="Salas Coronado, Raul" uniqKey="Salas Coronado R" first="Raúl" last="Salas-Coronado">Raúl Salas-Coronado</name><affiliation><nlm:affiliation>Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca, México. Dirección: km 2,5 Huajuapan de León, Oaxaca, México, Código postal: 69000. Email: rsalas@mixteco.utm.mx. ORCID: 0000-0002-5458-0157.</nlm:affiliation><wicri:noCountry code="subField">Código postal: 69000</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33017386</idno><idno type="pmid">33017386</idno><idno type="doi">10.5867/medwave.2020.08.8037</idno><idno type="wicri:Area/Main/Corpus">000B00</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B00</idno><idno type="wicri:Area/Main/Curation">000B00</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000B00</idno><idno type="wicri:Area/Main/Exploration">000B00</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19.</title><author><name sortKey="Santos Sanchez, Norma Francenia" sort="Santos Sanchez, Norma Francenia" uniqKey="Santos Sanchez N" first="Norma Francenia" last="Santos-Sánchez">Norma Francenia Santos-Sánchez</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca, México. ORCID: 0000-0001-5094-0488.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Mexique</country><wicri:regionArea>Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca</wicri:regionArea><wicri:noRegion>Oaxaca</wicri:noRegion></affiliation></author><author><name sortKey="Salas Coronado, Raul" sort="Salas Coronado, Raul" uniqKey="Salas Coronado R" first="Raúl" last="Salas-Coronado">Raúl Salas-Coronado</name><affiliation><nlm:affiliation>Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca, México. Dirección: km 2,5 Huajuapan de León, Oaxaca, México, Código postal: 69000. Email: rsalas@mixteco.utm.mx. ORCID: 0000-0002-5458-0157.</nlm:affiliation><wicri:noCountry code="subField">Código postal: 69000</wicri:noCountry></affiliation></author></analytic><series><title level="j">Medwave</title><idno type="eISSN">0717-6384</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors (MeSH)</term><term>Betacoronavirus (classification)</term><term>Betacoronavirus (isolation & purification)</term><term>COVID-19 (MeSH)</term><term>COVID-19 Testing (MeSH)</term><term>COVID-19 Vaccines (MeSH)</term><term>Clinical Laboratory Techniques (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Risk Factors (MeSH)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (classification)</term><term>Betacoronavirus (isolement et purification)</term><term>Facteurs de risque (MeSH)</term><term>Facteurs âges (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (diagnostic)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (diagnostic)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Techniques de laboratoire clinique (MeSH)</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>COVID-19</term><term>COVID-19 Testing</term><term>COVID-19 Vaccines</term><term>Clinical Laboratory Techniques</term><term>Humans</term><term>Pandemics</term><term>Risk Factors</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="fr"><term>Betacoronavirus</term><term>Facteurs de risque</term><term>Facteurs âges</term><term>Humains</term><term>Pandémies</term><term>Techniques de laboratoire clinique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes COVID-19 (Coronavirus disease 2019). This disease was detected in the city of Wuhan in China in December 2019. People infected with COVID-19 shows varying manifestations, depending on their health and age. The most common symptoms are fever, cough, myalgia, fatigue, odynophagia, and dyspnea. Infected adults older 60 years of age are the group of patients most susceptible to severe COVID-19 states and present comor-bidity in the presence of chronic diseases. On the other hand, it is also essential to have tests to detect SARS-COV-2 in people and follow the evolution of COVID-19 quickly, reliably, and cheap. To achieve this, there are real-time reverse transcription pol-ymerase chain reaction (RT-PCR) tests, isothermal nucleic acid amplification, and enzyme immunostimulation. Currently, there are no drug treatments to prevent infection and to combat the virus's effects. However, different research groups that are conduct-ing in vitro, in vivo, and in silico tests to find drugs able to provide an immune response and to control infection in humans with SARS-CoV-2. Chloroquine, hydroxychloroquine, remdesivir, interferon-2b, and oseltamivir are some pharmacological options evaluated in clinical trials for prophylaxis of COVID-19. The purpose of this review is to establish a reference framework for taxonomic classification of SARS-CoV-2 and the relationship they have with other CoVs, as well as their structure and propaga-tion pathways in humans. The characteristics and symptoms presented by patients with COVID-19, the detection methods, and possible treatments are also presented.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33017386</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">0717-6384</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Medwave</Title><ISOAbbreviation>Medwave</ISOAbbreviation></Journal><ArticleTitle>Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19.</ArticleTitle><Pagination><MedlinePgn>e8037</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5867/medwave.2020.08.8037</ELocationID><Abstract><AbstractText>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes COVID-19 (Coronavirus disease 2019). This disease was detected in the city of Wuhan in China in December 2019. People infected with COVID-19 shows varying manifestations, depending on their health and age. The most common symptoms are fever, cough, myalgia, fatigue, odynophagia, and dyspnea. Infected adults older 60 years of age are the group of patients most susceptible to severe COVID-19 states and present comor-bidity in the presence of chronic diseases. On the other hand, it is also essential to have tests to detect SARS-COV-2 in people and follow the evolution of COVID-19 quickly, reliably, and cheap. To achieve this, there are real-time reverse transcription pol-ymerase chain reaction (RT-PCR) tests, isothermal nucleic acid amplification, and enzyme immunostimulation. Currently, there are no drug treatments to prevent infection and to combat the virus's effects. However, different research groups that are conduct-ing in vitro, in vivo, and in silico tests to find drugs able to provide an immune response and to control infection in humans with SARS-CoV-2. Chloroquine, hydroxychloroquine, remdesivir, interferon-2b, and oseltamivir are some pharmacological options evaluated in clinical trials for prophylaxis of COVID-19. The purpose of this review is to establish a reference framework for taxonomic classification of SARS-CoV-2 and the relationship they have with other CoVs, as well as their structure and propaga-tion pathways in humans. The characteristics and symptoms presented by patients with COVID-19, the detection methods, and possible treatments are also presented.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Santos-Sánchez</LastName><ForeName>Norma Francenia</ForeName><Initials>NF</Initials><AffiliationInfo><Affiliation>Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca, México. ORCID: 0000-0001-5094-0488.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salas-Coronado</LastName><ForeName>Raúl</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca, México. Dirección: km 2,5 Huajuapan de León, Oaxaca, México, Código postal: 69000. Email: rsalas@mixteco.utm.mx. ORCID: 0000-0002-5458-0157.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Origen, características estructurales, medidas de prevención, diagnóstico y fármacos potenciales para prevenir y controlar COVID-19.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Chile</Country><MedlineTA>Medwave</MedlineTA><NlmUniqueID>101581949</NlmUniqueID><ISSNLinking>0717-6384</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019411" MajorTopicYN="Y">Clinical Laboratory Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>El síndrome respiratorio agudo severo coronavirus 2 (SARS-CoV-2) es responsable de la enfermedad denominada COVID-19 (acrónimo del inglés Coronavirus Disease-2019). Esta enfermedad fue detectada inicialmente en la ciudad de Wuhan, China en diciembre de 2019. Las personas contagiadas con COVID-19 presentan síntomas variados, dependiendo de su estado de salud y edad. Los síntomas más comunes son fiebre, tos, mialgia, fatiga, odinofagia y disnea. También se ha observado que en algunos pacientes, la infección es asintomática. Los adultos mayores de 60 años infectados son el grupo de pacientes más susceptibles a desarrollar estados severos de COVID-19 y se presenta comorbilidad en presencia de enfermedades crónicas. Por otra parte, también es importante disponer de pruebas que permitan detectar al SARS-COV-2 y seguir la evolución de COVID-19 de forma rápida, confiable y barata. Para lograr esto, existen pruebas de reacción en cadena de la polimerasa de transcripción inversa en tiempo real (RT-PCR), de amplificación isotérmica de ácido nucleico y de inmunoestimulación enzimática. Actualmente, no existen tratamientos para la prevención del contagio y combatir los efectos del virus en la salud humana. Sin embargo, en el mundo hay grupos de investigación que están realizando pruebas in vitro, in vivo e in silico para encontrar fármacos que sean capaces de prevenir y/o controlar la infección en humanos con SARS-CoV-2. La cloroquina, hidroxicloroquina, remdesivir, interferon-2b y oseltamivir son algunas de las opciones farmacológicas que están siendo evaluadas en pruebas clínicas para la profilaxis de COVID-19. El objetivo de la presente revisión consiste en establecer un marco de referencia de la clasificación taxonómica del SARS-CoV-2 y la relación que guardan con otros coronavirus, así como su estructura y forma de propagarse en el ser humano. También se presentan las características y síntomas de pacientes con COVID-19, los métodos de detección y potenciales tratamientos.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N"> Antiviral agents</Keyword><Keyword MajorTopicYN="N"> Mechanism of action</Keyword><Keyword MajorTopicYN="N"> SARS-CoV-2</Keyword><Keyword MajorTopicYN="N"> SARS-CoV-2 testing</Keyword><Keyword MajorTopicYN="N"> Transmission</Keyword><Keyword MajorTopicYN="N">Betacoronavirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>5</Day><Hour>17</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33017386</ArticleId><ArticleId IdType="pii">e8037</ArticleId><ArticleId IdType="doi">10.5867/medwave.2020.08.8037</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Mexique</li></country></list><tree><noCountry><name sortKey="Salas Coronado, Raul" sort="Salas Coronado, Raul" uniqKey="Salas Coronado R" first="Raúl" last="Salas-Coronado">Raúl Salas-Coronado</name></noCountry><country name="Mexique"><noRegion><name sortKey="Santos Sanchez, Norma Francenia" sort="Santos Sanchez, Norma Francenia" uniqKey="Santos Sanchez N" first="Norma Francenia" last="Santos-Sánchez">Norma Francenia Santos-Sánchez</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33017386
|texte= Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33017386" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |